Clinical Trial Update: Complement Inhibitor Eculizumab in Clinical Islet Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial update on complement inhibitor eculizumab in clinical islet transplantation for diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Uppsala University | Conditions: Diabetes Mellitus | Phase 2 | Status: COMPLETED